Sunday, March 2, 2014
Four Season Hotel
Boston, MASS
Welcome: Peter Kim, NIH/NIAID/TRP
Why are long acting/extended release ARVs a priority?
[video/slides] [audio-only/slide]
Summary: Tia Morton, NIH/NIAID/TRP
Summary of the Miami Meeting
[audio-only/slide]
Goals and Objectives: Charles Flexner, JHU - Chair
Goals and objectives of this meeting and status of
current LA antiretroviral development programs?
[video/slides] [audio-only/slide]
William Spreen, GSK/Viiv
Update on the development of GSK744
[video/slides] [audio-only/slide]
Peter Williams, Tibotec/Janssen
Update on the development of rilpivirine LA
[video/slides] [audio-only/slide]
Andrew Owen, U Liverpool
A flexible and scalable alternative to nanomilling for
formation of solid drug nanoparticles
[video/slides] [audio-only/slide]
Rodney Ho, U of Washington Nanocarrier
Long acting anti-HIV particles containing lopinavir, Ritonavir and tenofovir for
systemic and lymphoid tissue/cell exposure
[video/slides] [audio-only/slide]
Patrick Sinko, Rutgers and Ernest Amario School of Pharmacy
Approaches for targeting HIV-infected cells: reducing dose requirements and
prolonging target cell exposure
[video/slides] [audio-only/slide]
Howard Gendelman, UNMC
Pathways to chemical eradication of HIV infection: the role of long acting resevoir
targeting antiretroviral therapy
[video/slides] [audio-only/slide]
Glenn Triesman, JHU
Long-acting infectable treatments for schizophrenia
[audio-only/slide]
Jeff Hrkach, Bind Therapeutics
Bind 014
[video/slides] [audio-only/slide]
Randy Tressler, NIH/NIAID/DAIDS-HJF/TRP
Discussion of draft TPP molecular profile)
[video/slides] [audio-only/slide]
Simon Collins, i-Base
A community perspective on long acting/extended release ARVs
[video/slides] [audio-only/slide]
BREAKOUT SESSIONS - PDF - [Questions Here]
[video/slides] [audio-only/slide]